Literature DB >> 18337309

Deleterious effects of endogenous and exogenous testosterone on mesenchymal stem cell VEGF production.

Rinki Ray1, Christine M Herring, Troy A Markel, Paul R Crisostomo, Meijing Wang, Brent Weil, Tim Lahm, Daniel R Meldrum.   

Abstract

Modulating the paracrine effects of bone marrow mesenchymal stem cells (BMSCs) may be important for the treatment of ischemic myocardial tissue. In this regard, endogenous estrogen may enhance BMSC vascular endothelial growth factor (VEGF) production. However, little information exists regarding the effect of testosterone on stem cell function. We hypothesized that 1) endogenous or exogenous estrogen will enhance stem cell production of VEGF and 2) endogenous or exogenous testosterone will inhibit BMSC VEGF production. BMSCs were collected from adult male, female, castrated male, and ovariectomized female rats. One hundred thousand cells were incubated with testosterone (1, 10, or 100 nM) or estrogen (0.15, 1.5, or 15 nM) for 48 h. Cell supernatants were collected, and VEGF was measured by ELISA. BMSCs harvested from castrated males, normal females, and ovariectomized females produced more VEGF compared with normal males. Castration was associated with the highest level (1,018 +/- 98.26 pg/ml) of VEGF production by BMSCs, which was significantly more than that produced by BMSCs harvested from normal male and normal female animals. Exogenous testosterone significantly reduced VEGF production in BMSCs harvested from ovariectomized females in a dose-dependent manner. Exogenous estrogen did not alter BMSC VEGF production. These findings suggest that testosterone may work on BMSCs to decrease protective growth factor production and that effective removal of testosterone's deleterious effects via castration may prove to be beneficial in terms of protective factor production. By manipulating the mechanisms that BMSCs use to produce growth factors, we may be able to engineer stem cells to produce maximum growth factors during therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337309     DOI: 10.1152/ajpregu.00897.2007

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  6 in total

Review 1.  Gender dimorphisms in progenitor and stem cell function in cardiovascular disease.

Authors:  Jeremy L Herrmann; Aaron M Abarbanell; Brent R Weil; Mariuxi C Manukyan; Jeffrey A Poynter; Yue Wang; Arthur C Coffey; Daniel R Meldrum
Journal:  J Cardiovasc Transl Res       Date:  2010-04       Impact factor: 4.132

2.  Female stem cells are superior to males in preserving myocardial function following endotoxemia.

Authors:  Mariuxi C Manukyan; Brent R Weil; Yue Wang; Aaron M Abarbanell; Jeremy L Herrmann; Jeffrey A Poynter; Benjamin D Brewster; Daniel R Meldrum
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-03-30       Impact factor: 3.619

3.  High glucose concentration in cell culture medium does not acutely affect human mesenchymal stem cell growth factor production or proliferation.

Authors:  Brent R Weil; Aaron M Abarbanell; Jeremy L Herrmann; Yue Wang; Daniel R Meldrum
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-04-22       Impact factor: 3.619

4.  TNFR1 signaling resistance associated with female stem cell cytokine production is independent of TNFR2-mediated pathways.

Authors:  Troy A Markel; Paul R Crisostomo; Meijing Wang; Yue Wang; Tim Lahm; Nathan M Novotny; Jiangning Tan; Daniel R Meldrum
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-08-06       Impact factor: 3.619

5.  Effect of dihydrotestosterone on cultured human tenocytes from intact supraspinatus tendon.

Authors:  Vincenzo Denaro; Laura Ruzzini; Umile Giuseppe Longo; Francesco Franceschi; Barbara De Paola; Achille Cittadini; Nicola Maffulli; Alessandro Sgambato
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2009-10-27       Impact factor: 4.342

Review 6.  Critical Role of Tumor Necrosis Factor Signaling in Mesenchymal Stem Cell-Based Therapy for Autoimmune and Inflammatory Diseases.

Authors:  Li Yan; Dejin Zheng; Ren-He Xu
Journal:  Front Immunol       Date:  2018-07-20       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.